Document is current

Article History

Received: 24 June 2025

Accepted: 9 October 2025

First Online: 4 November 2025

Declarations

:

: GLP general toxicology studies in rats and NHPs were conducted at WuXi AppTec (Suzhou, China). The protocol and any amendments or procedures involving the care or use of animals in this study were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) prior to the initiation of such procedures. A staff veterinarian monitored the study for animal welfare issues. All mouse studies were carried out under a UK Home Office project license (PP3890603) ethically reviewed and approved by the local ethics committee (University of Sheffield Animal Welfare and Ethical Review Body). All individuals held the appropriate UK Home Office personal license and had appropriate training for procedures. All work was carried out under the terms of the UK Animals (Scientific Procedures) Act 1986 and animals were housed and maintained in line with Home Office Code of Practice for House and Care of Animals Used in Scientific Procedures. All procedures were reviewed by the University of Sheffield. Human CNS post-mortem tissue was obtained from the Sheffield Brain Tissue Bank with Research Ethics Committee approval (Sheffield Brain Bank –SBB-, Ethics Committee reference 08/MRE00/103). Human CSF was obtained from the University of Sheffield Biorepository with Research Ethics Committee approval number STH16573. Fibroblasts were collected from skin biopsies donated by ALS patients and controls with informed consent (Ethical Committee approval references: 12/YH/0330; 16/LO/2136).

: PCT/US2019/056996 - Treatment of Neurodegenerative diseases. Inventors: Ning Shan, Richard Mead, Laura Ferraiuolo, Pamela J Shaw. This covers the mechanism of action of a drug identified at SITraN for the treatment of neurodegenerative diseases, including ALS. Submitted in 2019. PCT/US2019/056998 - Treatment of Neurodegenerative diseases. Inventors: Laura Ferraiuolo, Ning Shan, Pamela J Shaw. This covers the specific properties of a neuroprotective compound identified at SITraN. Submitted in 2019. PCT/US2020/45321 - Pharmaceutical Composition For Use In The Treatment Of Neurological Diseases. Inventor: Ning Shan. This covers the pharmaceutical compositions and associated pharmacokinetics of a drug identified at SITraN. Submitted in 2019.

: PJS is a member of the Scientific Advisory Board for Aclipse Therapeutics and PJS, RJM and LF are share-holders of Aclipse Therapeutics.NS and INK are employees of Aclipse Therapeutics.